I-mab Stock Company Profile

Description

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.